Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
2 files | 3.40 MB
Add to list
  1. Search results
  2. Recent insights into viral infections...

Recent insights into viral infections as a trigger and accelerator in Alzheimer's disease

Lize De Vlieger (UGent) , Roosmarijn Vandenbroucke (UGent) and Lien Van Hoecke (UGent)
(2022) DRUG DISCOVERY TODAY. 27(11).
Author
Organization
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which only symptomatic medication is available, except for the recently FDA-approved aducanumab. This lack of effective treatment urges us to investigate alternative paths that might contribute to disease development. In light of the recent SARS-CoV-2 pandemic and the disturbing neurological complications seen in some patients, it is desirable to (re)investigate the viability of the viral infection theory claiming that a microbe could affect AD initiation and/or progression. Here, we review the most important evidence for this theory with a special focus on two viruses, namely HSV-1 and SARS-CoV-2. Moreover, we discuss the possible involvement of extracellular vesicles (EVs). This overview will contribute to a more rational approach of potential treatment strategies for AD patients.
Keywords
Drug Discovery, Pharmacology, Alzheimer's disease, Viral infection theory, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Herpes simplex virus, HSV, SIMPLEX-VIRUS TYPE-1, HIV-TAT PROTEIN, SYSTEMIC INFLAMMATION, TRANSGENIC MICE, AMYLOID-BETA, BRAIN COMMUNICATION, NLRP3 INFLAMMASOME, COGNITIVE FUNCTION, MOUSE MODEL, RISK

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • application/octet-stream
    • |
    • 970.51 KB
  • Download
    AAM DeVlieger.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • application/octet-stream
    • |
    • 2.43 MB

Citation

Please use this url to cite or link to this publication:

MLA
De Vlieger, Lize, et al. “Recent Insights into Viral Infections as a Trigger and Accelerator in Alzheimer’s Disease.” DRUG DISCOVERY TODAY, vol. 27, no. 11, 2022, doi:10.1016/j.drudis.2022.103340.
APA
De Vlieger, L., Vandenbroucke, R., & Van Hoecke, L. (2022). Recent insights into viral infections as a trigger and accelerator in Alzheimer’s disease. DRUG DISCOVERY TODAY, 27(11). https://doi.org/10.1016/j.drudis.2022.103340
Chicago author-date
De Vlieger, Lize, Roosmarijn Vandenbroucke, and Lien Van Hoecke. 2022. “Recent Insights into Viral Infections as a Trigger and Accelerator in Alzheimer’s Disease.” DRUG DISCOVERY TODAY 27 (11). https://doi.org/10.1016/j.drudis.2022.103340.
Chicago author-date (all authors)
De Vlieger, Lize, Roosmarijn Vandenbroucke, and Lien Van Hoecke. 2022. “Recent Insights into Viral Infections as a Trigger and Accelerator in Alzheimer’s Disease.” DRUG DISCOVERY TODAY 27 (11). doi:10.1016/j.drudis.2022.103340.
Vancouver
1.
De Vlieger L, Vandenbroucke R, Van Hoecke L. Recent insights into viral infections as a trigger and accelerator in Alzheimer’s disease. DRUG DISCOVERY TODAY. 2022;27(11).
IEEE
[1]
L. De Vlieger, R. Vandenbroucke, and L. Van Hoecke, “Recent insights into viral infections as a trigger and accelerator in Alzheimer’s disease,” DRUG DISCOVERY TODAY, vol. 27, no. 11, 2022.
@article{8766337,
  abstract     = {{Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which only symptomatic medication is available, except for the recently FDA-approved aducanumab. This lack of effective treatment urges us to investigate alternative paths that might contribute to disease development. In light of the recent SARS-CoV-2 pandemic and the disturbing neurological complications seen in some patients, it is desirable to (re)investigate the viability of the viral infection theory claiming that a microbe could affect AD initiation and/or progression. Here, we review the most important evidence for this theory with a special focus on two viruses, namely HSV-1 and SARS-CoV-2. Moreover, we discuss the possible involvement of extracellular vesicles (EVs). This overview will contribute to a more rational approach of potential treatment strategies for AD patients.}},
  articleno    = {{103340}},
  author       = {{De Vlieger, Lize and Vandenbroucke, Roosmarijn and Van Hoecke, Lien}},
  issn         = {{1359-6446}},
  journal      = {{DRUG DISCOVERY TODAY}},
  keywords     = {{Drug Discovery,Pharmacology,Alzheimer's disease,Viral infection theory,Severe acute respiratory syndrome coronavirus 2,SARS-CoV-2,Herpes simplex virus,HSV,SIMPLEX-VIRUS TYPE-1,HIV-TAT PROTEIN,SYSTEMIC INFLAMMATION,TRANSGENIC MICE,AMYLOID-BETA,BRAIN COMMUNICATION,NLRP3 INFLAMMASOME,COGNITIVE FUNCTION,MOUSE MODEL,RISK}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{15}},
  title        = {{Recent insights into viral infections as a trigger and accelerator in Alzheimer's disease}},
  url          = {{http://doi.org/10.1016/j.drudis.2022.103340}},
  volume       = {{27}},
  year         = {{2022}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: